stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Century Therapeutics, Inc.

United States · NASDAQ: IPSC · Market cap: · P/E: · P/S:

Century Therapeutics makes off-the-shelf cell therapies from engineered stem cells to treat cancer and autoimmune diseases.

Century Therapeutics is a biotech company trying to turn cell therapy into something you can buy off a shelf. Most cutting-edge cell treatments today are made from a patient's own cells, which means a slow, expensive, one-person-at-a-time manufacturing process. Century instead starts with induced pluripotent stem cells — ordinary cells that have been reprogrammed back into a blank, flexible state — and engineers them into natural killer cells and T cells that can be grown in large batches and given to many patients.

Century Therapeutics, Inc. (IPSC) Allogeneic iPSC-derived cell therapies: line art illustration of A vial of engineered iPSC-derived cell therapy with a cell cluster logo and a small islet-cell capsule icon on its label
iPSC cell therapies
Century grows cell therapies from engineered stem cells to treat diabetes and cancer.

The pitch is simple: make powerful immune cells that attack cancer and, more recently, autoimmune disease, but do it at scale so treatment is faster, cheaper, and available when a patient needs it. Century engineers these cells with features meant to help them survive in the body and avoid being rejected, and it pairs them with drugs that help them work better. The company's lead programs target blood cancers and autoimmune conditions, and it has pushed into autoimmune disease because the same cells that kill cancer can also quiet a misbehaving immune system.


This is a pre-revenue, clinical-stage story, not a business with sales yet. Century's money comes from investors and partnerships, and its fortunes rise and fall on trial data and whether it can keep funding expensive experiments. Biotech peers and rivals include other allogeneic cell therapy players such as Fate Therapeutics, plus larger companies developing similar treatments. The bet is that standardized, off-the-shelf cell therapy eventually beats the bespoke approach — but the science and the cash runway are the real risks.

Saved answer · last researched 16 Nov 2026